+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Estradiol Regulation of Somatostatin Receptors in the Arcuate Nucleus of the Female Rat

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Somatostatin receptors on lactotroph cells of the anterior pituitary are positively regulated by estradiol. In the present work, we investigated whether estradiol regulation of somatostatin receptors also occurred in the female rat brain. <sup>125</sup>I-Tyr₀-DTrp<sub>8</sub>-somatostatin (<sup>125</sup>I-SRIF: 780 Ci/mM ) was used as a ligand. Female adult rats were ovariectomized and treated or not with estradiol benzoate (20 µg/day for 1 or 8 days). In female brains, <sup>125</sup>I-SRIF binding, as assessed by film radioautography, was high in the basolateral amygdala, CA1 field and dentate gyms of the hippocampus and locus coeruleus, moderate in the median habenula and deep layers all through the cortex. Castration or estradiol treatment did not modify <sup>125</sup>I-SRIF binding in these regions. By light-microscopic radioautography, a subpopulation of <sup>125</sup>I-SRIF-labeled cells was localized in the ventrolateral portion of the arcuate nucleus. Ovariectomy alone did not significantly affect the number and binding density of <sup>125</sup>I-SRIF-labeled cells in the arcuate nucleus. However, estradiol treatment in ovariectomized animals significantly increased both parameters. Along the estrus cycle, the number of <sup>125</sup>I-SRIF-labeled cells was not significantly modified but <sup>125</sup>I-SRIF binding density was significantly higher in proestrus as compared to diestrus I, diestrus II and estrus. These results demonstrate that brain <sup>125</sup>I-SRIF binding sites are positively regulated by estradiol only in the arcuate nucleus of the hypothalamus.

          Related collections

          Author and article information

          S. Karger AG
          07 April 2008
          : 56
          : 2
          : 240-245
          U. 159 INSERM, Paris, France
          126234 Neuroendocrinology 1992;56:240–245
          © 1992 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 6
          Original Paper


          Comment on this article